Schisandrin A
Based on 14 publication(s) in Google Scholar
Schisandrin A inhibits CYP3A activity with an IC50 of 6.60 μM and Ki of 5.83 μM, respectively.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.89%
- CAS. Nr.: 61281-38-7
- Formel: C24H32O6
- Molecular Weight:416.51
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-N0691
SchisandrinAutophagy Inducer -
HY-N0694
Schisantherin ANF-κB Inhibitor -
HY-N0045
Ginsenoside Rg1Apoptosis Inducer -
HY-N0089
Schisandrin BAntioxidant -
HY-N0692
Schisandrol BHepato-protective Agent -
HY-N0607
Ginsenoside RoCalcium Channel Antagonist -
HY-B0215
AcetylcysteineMucolytic Agent -
HY-Y0320
Dimethyl sulfoxide, meets analytical specification of Ch.P.Aprotic Solvent -
HY-N0014
IcariinPPAR Activator -
HY-10529
Betulinic acidApoptosis Inducer -
HY-N0156
Oleanolic acidAutophagy Inducer -
HY-N0690
Schisandrin CBioactive Lignan
Publications Citing Use of MedChemExpress (MCE) Schisandrin A
More- Engineering. 2026 May 20.
- Phytomedicine. 2025 May:140:156484. [Abstract]
- Int J Nanomedicine. 2026 Jul 9:21:611321.
- Cell Prolif. 2020 Oct;53(10):e12882. [Abstract]
- Eur J Pharmacol. 2019 Jul 15:855:10-19. [Abstract]
- Front Cell Dev Biol. 2021 Nov 10;9:763864. [Abstract]
- Sci Rep. 2019 Dec 16;9(1):19173. [Abstract]
- Eur J Med Res. 2023 Jul 3;28(1):217. [Abstract]
- Biosci Rep. 2020 Mar 27;40(3):BSR20200203. [Abstract]
- Biochem Biophys Rep. 2026 Jan 15:45:102454. [Abstract]
- J Immunol Res. 2022 May 25:2022:3079823. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Biosci Biotechnol Biochem. 2026 Jan 29:zbag018. [Abstract]
- Pharmacogn Mag. 2023 Apr 14.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Histological Imaging/Staining
-
IF
-
WB
-
Flow Cytometry
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
CYP3A 6.6 μM (IC50) |
Autophagy |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>100 μM
Compound: Schisandrin A
|
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 18063366] |
| HCT-15 | IC50 |
>100 μM
Compound: Schisandrin A
|
Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay
Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay
|
[PMID: 18063366] |
| HL60/ADR | IC50 |
2036 ng/mL
Compound: Schisandrin A
|
TP_TRANSPORTER: inhibition of VP-16 transport in HL60/ADR cells (overexpression of MRP1)
TP_TRANSPORTER: inhibition of VP-16 transport in HL60/ADR cells (overexpression of MRP1)
|
[PMID: 17129588] |
| HL60/ADR | IC50 |
4.1 ng/mL
Compound: Schisandrin A
|
TP_TRANSPORTER: inhibition of VCR transport in HL60/ADR cells (overexpression of MRP1)
TP_TRANSPORTER: inhibition of VCR transport in HL60/ADR cells (overexpression of MRP1)
|
[PMID: 17129588] |
| HL60/ADR | IC50 |
59 ng/mL
Compound: Schisandrin A
|
TP_TRANSPORTER: inhibition of DNR transport in HL60/ADR cells (overexpression of MRP1)
TP_TRANSPORTER: inhibition of DNR transport in HL60/ADR cells (overexpression of MRP1)
|
[PMID: 17129588] |
| K562 | IC50 |
>100 μM
Compound: Schisandrin A
|
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 18063366] |
| MDA-MB-231 | IC50 |
>100 μM
Compound: Schisandrin A
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
|
[PMID: 18063366] |
| SK-HEP1 | IC50 |
42 μM
Compound: Schisandrin A
|
Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay
Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay
|
[PMID: 18063366] |
| SNU-638 | IC50 |
53.1 μM
Compound: Schisandrin A
|
Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay
Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay
|
[PMID: 18063366] |
| T47D | IC50 |
40 μM
Compound: Schisandrin A
|
Antiproliferative activity against human T47D cells after 72 hrs by SRB assay
Antiproliferative activity against human T47D cells after 72 hrs by SRB assay
|
[PMID: 18063366] |
In Vitro
Schisandrin A (Sch A) strongly inhibits microsomal midazolam 1-hydroxylation catalyzed by CYP3A, with an IC50 of 6.60 μM. The recovery of enzyme activity in the absence or presence of Schisandrin A is shown in dilution assay plots. The Ki value for Schisandrin A is obtained from the Dixon plots and is 5.83 μM. The inactivation of rat liver microsomal midazolam 1-hydroxylation activity by Schisandrin A in the presence of NADPH is found to be time- and concentration-dependent. The Kinact and Ki are estimated to be 0.134/min and 4.51 μM, respectively for Schisandrin A[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 61281-38-7
-
Appearance Solid
-
Molecular Weight 416.51
-
Formel C24H32O6
-
Color White to off-white
-
SMILES
C[C@H]1CC2=CC(OC)=C(OC)C(OC)=C2C3=C(OC)C(OC)=C(OC)C=C3C[C@H]1C
-
Synonyms
Schizandrin-A; Wuweizisu-A; Deoxyschizandrin
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
-
Phytomedicine
Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]2025 May:140:156484. PMID: 40090046 -
-
Cell Prolif
Schisandrin A restrains osteoclastogenesis by inhibiting reactive oxygen species and activating Nrf2 signalling. [Abstract]2020 Oct;53(10):e12882. PMID: 32871020
Schisandrin A purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2020 Oct;53(10):e12882. [Abstract]
Representative images of TRAcP staining showing that Sch (Schisandrin A) (50-200 μM; 24-72 h) inhibited osteoclastogenesis dose‐dependently. BMMs were stimulated with M‐CSF and RANKL in the absence or presence of different concentrations of Sch.
Schisandrin A purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2020 Oct;53(10):e12882. [Abstract]
Schisandrin A (Sch) (100 mg/kg; every other day over 6 weeks). Representative images of bone cryosections showing DHE fluorescence in different groups.
Schisandrin A purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2020 Oct;53(10):e12882. [Abstract]
Schisandrin A (Sch) (100 mg/kg; every other day over 6 weeks). Immunofluorescence staining was performed to detect the expression of Nrf2. Nuclear translocations of Nrf2 were observed in the zoom pictures. Quantitative analysis of Nrf2 immunofluorescence intensity.
Schisandrin A purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2020 Oct;53(10):e12882. [Abstract]
Western Blot images of the effects of Sch on TRAF6, Nrf2, Nox1, catalase and HO‐1 expression. BMMs were stimulated by RANKL (50 ng/mL) in the absence or presence of Sch (Schisandrin A) (0, 50, 100, 200 μmol/L) for 2 d, and then, proteins were harvested for Western blot.
Schisandrin A purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2020 Oct;53(10):e12882. [Abstract]
Frequency of apoptotic cells of BMMs co‐cultured with 20 ng/mL M‐CSF and 50 ng/mL RANKL at the concentration of 200 μmol/L Sch (Schisandrin A) for 2 d (n = 3 per group).
-
Eur J Pharmacol
Schizandrin A enhances the efficacy of gefitinib by suppressing IKKβ/NF-κB signaling in non-small cell lung cancer. [Abstract]2019 Jul 15:855:10-19. PMID: 31028739
Schisandrin A purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2019 Jul 15:855:10-19. [Abstract]
HCC827GR cells were treated with Sch A (Schisandrin A) alone (20 or 40 μM), Gefi alone (15 μM) or treated with combination of Sch A (20 or 40 μM) and Gefi (15 μM) for 24 h, and the cell cycle distribution was analyzed by the cytometry (Becton Dickinson FACSCalibor, BD Biosciences, Franklin Lakes, NJ).
Schisandrin A purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2019 Jul 15:855:10-19. [Abstract]
After HCC827GR cells were treated with TNF-α (10 ng/mL) with or without Sch A (Schisandrin A) (20 and 40 μM) for 2 h, NF-κB p65 levels in the nucleus and cytoplasm were determined by Western blot.
-
Front Cell Dev Biol
Curdione and Schisandrin C Synergistically Reverse Hepatic Fibrosis via Modulating the TGF-β Pathway and Inhibiting Oxidative Stress. [Abstract]2021 Nov 10;9:763864. PMID: 34858986 -
Sci Rep
Schisandrin A protects intestinal epithelial cells from deoxynivalenol-induced cytotoxicity, oxidative damage and inflammation. [Abstract]2019 Dec 16;9(1):19173. PMID: 31844123 -
Eur J Med Res
Schisandrin A regulates the Nrf2 signaling pathway and inhibits NLRP3 inflammasome activation to interfere with pyroptosis in a mouse model of COPD. [Abstract]2023 Jul 3;28(1):217. PMID: 37400851 -
Biosci Rep
Schizandrin A exhibits potent anticancer activity in colorectal cancer cells by inhibiting heat shock factor 1. [Abstract]2020 Mar 27;40(3):BSR20200203. PMID: 32110802 -
Biochem Biophys Rep
2026 Jan 15:45:102454. PMID: 41584303 -
J Immunol Res
Deoxyschizandrin Inhibits the Proliferation, Migration, and Invasion of Bladder Cancer Cells through ALOX5 Regulating PI3K-AKT Signaling Pathway. [Abstract]2022 May 25:2022:3079823. PMID: 35664354 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Biosci Biotechnol Biochem
Schisandrin A alleviates chondrocyte senescence and extracellular matrix degeneration by suppressing PI3K/Akt signaling pathway. [Abstract]2026 Jan 29:zbag018. PMID: 41609406 -
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 50 mg/mL (120.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.00 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
Kinase Assay[1]
For the inactivation of CYP3A4 activity, microsomes are preincubated with inhibitors (Schisandrin A, 2.4 μM, 7.2 μM and 12.0 μM; or Sch B) at 37°C for up to 15 min in the presence of NADPH. Reactions are initiated with the addition of substrate midazolam and incubated at 37°C for 10 min. The enzyme inactivation is analyzed. Duplicates are prepared and tested[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration[2]
Rats[2]
Healthy male Sprague-Dawley rats, weighing 250-280 g and 2-3 months of age, are used. The rats are randomly divided into five groups with 16 rats in each group. The animals are administered once daily for three consecutive days. The Schisandrin A-treated groups are administered intragastrically with doses of 32, 16 or 8 mg/kg of Schisandrin A (physiological saline as vehicle), and the rats are similarly administered with equal volume of vehicle in the negative control group and Ketoconazole (75 mg/kg) in the positive control group. All animals are allowed free access to food but are fasted overnight before scarification to reduce the intestinal content, and each group is randomly divided into two parts with eight rats in each part[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Reinheit & Dokumentation
-
Data Sheet (286 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Li WL, et al. Inhibitory effects of Schisandrin A and Schisandrin B on CYP3A activity. Methods Find Exp Clin Pharmacol. 2010 Apr;32(3):163-9. [Content Brief]
[2]. Li WL, et al. Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat. Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):187-92. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4009 mL | 12.0045 mL | 24.0090 mL | 60.0226 mL |
| 5 mM | 0.4802 mL | 2.4009 mL | 4.8018 mL | 12.0045 mL | |
| 10 mM | 0.2401 mL | 1.2005 mL | 2.4009 mL | 6.0023 mL | |
| 15 mM | 0.1601 mL | 0.8003 mL | 1.6006 mL | 4.0015 mL | |
| 20 mM | 0.1200 mL | 0.6002 mL | 1.2005 mL | 3.0011 mL | |
| 25 mM | 0.0960 mL | 0.4802 mL | 0.9604 mL | 2.4009 mL | |
| 30 mM | 0.0800 mL | 0.4002 mL | 0.8003 mL | 2.0008 mL | |
| 40 mM | 0.0600 mL | 0.3001 mL | 0.6002 mL | 1.5006 mL | |
| 50 mM | 0.0480 mL | 0.2401 mL | 0.4802 mL | 1.2005 mL | |
| 60 mM | 0.0400 mL | 0.2001 mL | 0.4002 mL | 1.0004 mL | |
| 80 mM | 0.0300 mL | 0.1501 mL | 0.3001 mL | 0.7503 mL | |
| 100 mM | 0.0240 mL | 0.1200 mL | 0.2401 mL | 0.6002 mL |
Schisandrin A Related Classifications
HY-N0693 Related Classifications
Powered by Bioz